Dynavax Technologies (NASDAQ:DVAX) Rating Lowered to “Sell” at The Goldman Sachs Group

Dynavax Technologies (NASDAQ:DVAX) was downgraded by equities researchers at The Goldman Sachs Group from a “neutral” rating to a “sell” rating in a research report issued on Tuesday, MarketBeat.com reports. They presently have a $12.00 price objective on the biopharmaceutical company’s stock, down from their prior price objective of $15.00. The Goldman Sachs Group’s target price would suggest a potential downside of 3.61% from the stock’s current price.

Other equities analysts also recently issued reports about the stock. HC Wainwright upped their price target on shares of Dynavax Technologies from $29.00 to $31.00 and gave the company a “buy” rating in a research note on Tuesday, January 14th. StockNews.com upgraded shares of Dynavax Technologies from a “hold” rating to a “buy” rating in a research report on Tuesday, January 14th.

Dynavax Technologies Stock Performance

NASDAQ:DVAX opened at $12.45 on Tuesday. The stock has a 50 day simple moving average of $12.81 and a 200 day simple moving average of $11.92. The stock has a market cap of $1.64 billion, a P/E ratio of 95.78 and a beta of 1.32. Dynavax Technologies has a 1-year low of $9.74 and a 1-year high of $13.89. The company has a current ratio of 13.23, a quick ratio of 12.34 and a debt-to-equity ratio of 0.33.

Institutional Inflows and Outflows

Hedge funds and other institutional investors have recently bought and sold shares of the stock. Assenagon Asset Management S.A. acquired a new stake in Dynavax Technologies during the third quarter worth about $8,291,000. Norges Bank acquired a new stake in shares of Dynavax Technologies during the 4th quarter worth approximately $7,762,000. PDT Partners LLC bought a new position in Dynavax Technologies in the third quarter valued at approximately $3,967,000. WINTON GROUP Ltd raised its position in Dynavax Technologies by 339.0% during the fourth quarter. WINTON GROUP Ltd now owns 426,814 shares of the biopharmaceutical company’s stock valued at $5,450,000 after purchasing an additional 329,579 shares in the last quarter. Finally, Trexquant Investment LP lifted its stake in Dynavax Technologies by 48.7% during the fourth quarter. Trexquant Investment LP now owns 776,397 shares of the biopharmaceutical company’s stock worth $9,915,000 after purchasing an additional 254,405 shares during the last quarter. Institutional investors and hedge funds own 96.96% of the company’s stock.

Dynavax Technologies Company Profile

Dynavax Technologies Corporation, a commercial stage biopharmaceutical company, focuses on developing and commercializing vaccines in the United States. It markets HEPLISAV-B, a hepatitis B vaccine for prevention of infection caused by all known subtypes of hepatitis B virus in age 18 years and older in the United States and Europe.